Chronocort

Phase 3Small molecule

NNeurocrine UK Limited

Chronocort is one of 28 small molecule programs targeting Adrenal insufficiency. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Adrenal InsufficiencyActive, not recruiting

Congenital Adrenal HyperplasiaActive, not recruiting

Adrenal InsufficiencyPhase 2

Active, not recruiting

Congenital Adrenal HyperplasiaPhase 3

Active, not recruiting

Competition

Competitive Landscape

27 competitors in Congenital Adrenal Hyperplasia

#DrugCompanyPhaseTrials

Florinef

Alnylam Pharmaceuticals

Phase 3

2 2

Femara

Novartis

Phase 3

1 3

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

6 4

Eulexin

SSchering-Plough

Phase 3

1 5

Crenessity

Neurocrine Biosciences

Phase 3

4 6

Decadron

AAspen Global Incorporated

Phase 2

1 7

Teslac

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

1 8

Lu AF95245

Lundbeck

Phase 2

1 9

Zytiga

Johnson & Johnson

Phase 1

2 10

Chronocort

NNeurocrine UK Limited

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Congenital Adrenal Hyperplasia4 trials

Comparison of Two Forms of Hydrocortisone in Patients With Congenital Adrenal Hyperplasia

Completed·NNeurocrine UK Limited·Phase 1/2·NCT00519818·20 enrolled

Comparison of Chronocort Versus Standard Hydrocortisone Replacement Therapy in Participants Aged 16 Years and Over With Congenital Adrenal Hyperplasia

Completed·NNeurocrine UK Limited·Phase 3·NCT05063994·55 enrolled

Long-term Safety Study of Chronocort in the Treatment of Participants With Congenital Adrenal Hyperplasia

Completed·NNeurocrine UK Limited·Phase 3·NCT05299554·76 enrolled

Show 1 more trial

Comparison of Chronocort® With Standard Glucocorticoid Therapy in Patients With Congenital Adrenal Hyperplasia

Completed·NNeurocrine UK Limited·Phase 3·NCT02716818·122 enrolled

Adult1 trial

A Study of Chronocort® Versus Cortef ® in Healthy Adult Male Subjects

Completed·NNeurocrine UK Limited·Phase 1·NCT03343327·25 enrolled

Glucocorticoid1 trial

Open-label Comparison of Chronocort® Versus Standard Glucocorticoid Replacement Therapy

Withdrawn·NNeurocrine UK Limited·Phase 3·NCT03532022

Tics1 trial

A Two-part, Study to Compare the Pharmacokinetics and Dose Proportionality of up to 6 Chronocort Formulations

Completed·NNeurocrine UK Limited·Phase 1·NCT03051893·28 enrolled

Adrenal insufficiency1 trial

Chronocort Versus Plenadren Replacement Therapy in Adults With Adrenal Insufficiency

Completed·NNeurocrine UK Limited·Phase 2·NCT05222152·58 enrolled

1 more indication

Hydrocortisone1 trial

An Open Label Study in Healthy Volunteers to Compare Chronocort® to Hydrocortisone

Completed·NNeurocrine UK Limited·Phase 1·NCT03019614·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Chronocort. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Chronocort compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Chronocort. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Neurocrine UK Limited company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: NNeurocrine UK Limited

Chronocort

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Congenital Adrenal Hyperplasia4 trials

Adult1 trial

Glucocorticoid1 trial

Tics1 trial

Adrenal insufficiency1 trial

Hydrocortisone1 trial

References

Drug Info

Quick Facts

Related News